Wednesday, October 14, 2026

Economy

98 articles

Nobel Economist Acemoglu: AI's Productivity Boost Will Be 'Small'—A Problem for Markets Worldwide

Nobel Economist Acemoglu: AI's Productivity Boost Will Be 'Small'—A Problem for Markets Worldwide

Nobel laureate Daron Acemoglu projects AI will deliver only a modest productivity boost globally, directly contradicting how equity markets from New York to Tokyo are pricing the technology. His forecast lands against rising energy costs, sticky inflation at 3.8% CPI, and AI stocks posting outsized gains on exchanges worldwide. If Acemoglu is right, current AI valuations carry a credibility gap in every major market.

LM Salvado•
U.S. Social Security Insolvency Moves to 2032 as $1.1 Trillion in Tax Cuts Hit Federal Budget

U.S. Social Security Insolvency Moves to 2032 as $1.1 Trillion in Tax Cuts Hit Federal Budget

The One Big Beautiful Bill Act has accelerated U.S. Social Security insolvency by three years to 2032 while cutting $1.1 trillion from Medicaid and Affordable Care Act programs. The fiscal crisis arrives as Federal Reserve Chair Jerome Powell's term expires in May 2026, raising global concerns about monetary policy independence in the world's largest economy.

ViaNews Editorial Team•
Global Markets Surge as Fed Sees Tariff Impact Contained, Labor Softening

Global Markets Surge as Fed Sees Tariff Impact Contained, Labor Softening

Global equities rallied Thursday with tech and AI stocks leading gains after the Federal Reserve said tariffs have yet to spread beyond goods prices. San Francisco Fed President Mary Daly cited labor market softening and moderating wage growth as reason to avoid prolonged high rates. The divergence highlights tension between strong markets and weakening employment fundamentals.

ViaNews Editorial Team•
U.S. spending bill risks $5.5 trillion debt surge, threatens Social Security by 2032 amid global fiscal pressures

U.S. spending bill risks $5.5 trillion debt surge, threatens Social Security by 2032 amid global fiscal pressures

The One Big Beautiful Bill Act could add $5.5 trillion to U.S. national debt by 2034 and push Social Security insolvency forward to 2032, three years earlier than projected. The fiscal expansion comes as major economies globally face rising debt burdens, with U.S. commercial banks holding $4.4 trillion in government securities vulnerable to yield spikes.

ViaNews Editorial Team•
EUR/USD Slips Near 1.1500 Amid Cautious ECB Tone

EUR/USD Slips Near 1.1500 Amid Cautious ECB Tone

The EUR/USD pair extended its losses in the second consecutive trading session, trading near 1.1510 during Asian hours on Monday. Despite a cautious tone from the European Central Bank (ECB), the Euro Zone's economic recovery remains under pressure.

Via News Editorial•
Trump Announces 'Framework' to Cut Health Care Costs, Latest Developments in ACA Reforms

Trump Announces 'Framework' to Cut Health Care Costs, Latest Developments in ACA Reforms

President Trump is set to reveal details of his new health care plan aimed at curbing ACA premium costs, with key figures expected to unveil the 'Healthcare Price Cuts Act' at an early date. The proposal seeks to address the rising expenses of the Affordable Care Act, particularly affecting nearly 22 million Americans whose subsidies may expire soon. The announcement comes amid growing public support for extending tax credits and the potential for a separate bill enshrining the 'Most Favored Nation' drug pricing policy.

Via News Editorial•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com